ESMO 2017 | How is treatment determined in renal cell carcinoma?
Enrique Grande, MD, from the Ramon y Cajal University Hospital, Madrid, Spain, discusses treatment options for renal cell carcinoma (RCC) at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. There have been various studies investigating treatments in RCC, for example, the METEOR study (NCT01865747) which investigated the efficacy of cabozantinib, and the CheckMate 025 study (NCT01668784) investigated the efficacy of nivolumab. Currently, there are no biomarkers to determine which treatment path is best, and decisions are based on patient and tumor characteristics, such as comorbidities, tumor burden, and tolerability.
Get great new content delivered to your inboxSign up